Arcadia Biosciences CEO Jacot appointed to board; shareholders re-elect directors, ratify auditor, approve executive pay

Arcadia Biosciences, Inc.

CEO Stanley E. Jacot, Jr. appointed as Class III director to fill vacancy from Matthew Plavan's Dec 2021 resignation.
Annual meeting held June 1, 2022 with 54.40% of outstanding shares present.
Albert Bolles and Kevin Comcowich elected as Class I directors with 5.5M and 6.1M votes for respectively.
Deloitte & Touche LLP ratified as auditor for FY2022 with 11.9M votes for, 90k against.
Say-on-pay advisory vote approved with 5.3M for, 1.3M against, 109k abstain.

item 5.02 item 5.07

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Stanley E. Jacot, Jr.

Class III Director

RKDA · Arcadia Biosciences, Inc.

Effective: 2022-06-02
Filed: June 7, 2022, 7:59 PM ET

On June 2, 2022, Arcadia’s board of directors appointed Stanley E. Jacot, Jr., Arcadia’s current president and chief executive officer, to serve as a Class III director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stanley E. Jacot, Jr. was appointed as Class III Director at Arcadia Biosciences, Inc..

Action: appointed
Role: Class III Director

Exact text from the filing

On June 2, 2022, Arcadia’s board of directors appointed Stanley E. Jacot, Jr., Arcadia’s current president and chief executive officer, to serve as a Class III director of the Company.

View on SEC.gov

Arcadia Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-011278

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.